TrialHaematologica2020

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.

Alessandra Larocca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.